Medicenna Therapeutics Corp (MDNA)

2.490
+0.005(+0.20%)
  • Volume:
    36,893
  • Bid/Ask:
    2.480/2.500
  • Day's Range:
    2.440 - 2.490

MDNA Overview

Prev. Close
2.485
Day's Range
2.44-2.49
Revenue
-
Open
2.52
52 wk Range
1.85-6.79
EPS
-
Volume
36,893
Market Cap
132.48M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
134,466
P/E Ratio
-
Beta
-
1-Year Change
-39.39%
Shares Outstanding
53,742,255
Next Earnings Date
Nov 02, 2021
What is your sentiment on Medicenna Therapeutics Corp?
or
Vote to see community's results!

Medicenna Therapeutics Corp News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyNeutralStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Medicenna Therapeutics Corp Company Profile

Medicenna Therapeutics Corp Company Profile

Employees
13
Market
Canada

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Read More
  • pls,what is eps?
    0
    • 🚀 off we go
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.